Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

(2015) Susan D. Richman et al.   Analytical Cellular Pathology

Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer

(2013) Issa J. Dahabreh et al.   ANNALS OF INTERNAL MEDICINE

Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach

(2012) Mark P. LeGolvan et al.   HUMAN PATHOLOGY

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu

(2012) Sebastian Stintzing et al.   INTERNATIONAL JOURNAL OF CANCER

Hurdles and Complexities of Codon 13 KRAS Mutations

(2012) Maria Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

(2012) Sabine Tejpar et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer

(2012) Takeru Shiroiwa et al.   Molecular Diagnosis & Therapy

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

(2011) N Knijn et al.   BRITISH JOURNAL OF CANCER

KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective

(2011) P. R. Blank et al.   CLINICAL CANCER RESEARCH

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer

(2011) F. Aubin et al.   Current Oncology

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

(2011) Arthi Vijayaraghavan et al.   INTERNATIONAL JOURNAL OF CANCER

Should Oncologists Be Aware in Their Clinical Practice ofKRASMolecular Analysis?

(2011) Daniele Santini et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

SNaPshot and StripAssay as Valuable Alternatives to Direct Sequencing for KRAS Mutation Detection in Colon Cancer Routine Diagnostics

(2011) Arantza Fariña Sarasqueta et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detection of KRAS and BRAF Mutations in Colorectal Carcinoma

(2011) Maria Arcila et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Spotlight on Panitumumab in Metastatic Colorectal Cancer†

(2010) Gillian M. Keating   BIODRUGS

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

(2010) Sergio Rizzo et al.   CANCER TREATMENT REVIEWS

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

ACR Appropriateness Criteria®: Rectal Cancer—Metastatic Disease at Presentation

(2010) Joseph Herman et al.   CURRENT PROBLEMS IN CANCER

A comparability study of 5 commercial KRAS tests

(2010) Kelly Oliner et al.   Diagnostic Pathology

Panitumumab

(2010) Gillian M. Keating   DRUGS

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Mountain States Genetics Regional Collaborative Centerʼs Metabolic Newborn Screening Long-Term Follow-Up Study: A collaborative multi-site approach to newborn screening outcomes research

(2010) Erica L. Wright et al.   GENETICS IN MEDICINE

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

(2010) Dawn Odom et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patient With Colorectal Cancer With HeterogeneousKRASMolecular Status Responding to Cetuximab-Based Chemotherapy

(2010) Andrea Mancuso et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS and BRAF: drug targets and predictive biomarkers

(2010) Efsevia Vakiani et al.   JOURNAL OF PATHOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives

(2009)   GENETICS IN MEDICINE

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting

(2009) Vicki Whitehall et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

(2009) Gunnar Folprecht et al.   LANCET ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

(2008) M.-C. Etienne-Grimaldi et al.   CLINICAL CANCER RESEARCH

Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer

(2008) Salvatore Artale et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the epidermal growth factor receptor in metastatic colorectal cancer

(2007) Kimmie Ng et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY